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ABSTRACT
Short interfering RNAs (siRNA) guide degradation of
target RNA by the RNA-induced silencing complex
(RISC). The use of siRNA in animals is limited
partially due to the short half-life of siRNAs in
tissues. Chemically modified siRNAs are necessary
that maintain mRNA degradation activity, but are
more stable to nucleases. In this study, we utilized
alternating 20-O-methyl and 20-deoxy-20-fluoro (OMe/
F) chemically modified siRNA targeting PTEN and
Eg5. OMe/F-modified siRNA consistently reduced
mRNA and protein levels with equal or greater
potency and efficacy than unmodified siRNA. We
showed that modified siRNAs use the RISC mech-
anism and lead to cleavage of target mRNA at the
same position as unmodified siRNA. We further
demonstrated that siRNAs can compete with each
other, where highly potent siRNAs can compete with
less potent siRNAs, thus limiting the ability of
siRNAs with lower potency to mediate mRNA
degradation. In contrast, a siRNA with low potency
cannot compete with a highly efficient siRNA. We
established a correlation between siRNA potency
and ability to compete with other siRNAs. Thus,
siRNAs that are more potent inhibitors for mRNA
destruction have the potential to out-compete less
potent siRNAs indicating that the amount of a
cellular component, perhaps RISC, limits siRNA
activity.
INTRODUCTION
Short interfering RNAs (siRNA) are 21–23 nt long double
stranded RNA molecules that lead to degradation of speciﬁc
mRNAs through a multi-protein complex termed the RNA
induced silencing complex (RISC) (1). Once introduced
into cells, siRNAs are bound to the RISC complex and the
double stranded siRNA is unwound by the action of a
helicase. The resulting RISC-bound strand is then able to
duplex to a complementary mRNA, which leads to enzymatic
cleavage of the target mRNA, resulting in post-transcriptional
gene silencing. This cleavage is performed by Ago2
(eIF2C2), a RISC associated RNase (2). siRNA has become
a useful and widely used tool for gene function studies
in vitro (3). However, the use of siRNA for both gene func-
tion analysis in vivo and therapeutic development is limited
due to the poor pharmacodynamic and pharmacokinetic
properties, such as low stability due to serum nucleases and
poor delivery to tissues.
To overcome these limitations chemically modiﬁed siR-
NAs with improved pharmacodynamic and pharmacokinetic
properties and equal or greater potency have been identiﬁed
(4–7). These chemically modiﬁed siRNAs are more potent
than unmodiﬁed siRNAs and are much more stable to
serum nucleases. For example, 20-O-methyl (OMe) modiﬁca-
tions have been introduced into the antisense strand of tissue
factor siRNA (8–10). siRNA activity containing full OMe
substitutions in the sense strand combined with phosphoro-
thioate linkages has been shown to be mediated by RISC
and strand-speciﬁc loading or binding to hAgo2 may be
modulated through selective incorporation of these modiﬁca-
tions (11). Recently, a double strand siRNA construct which
has been fully modiﬁed on both strands with alternating OMe
and 20-ﬂuoro (F) nucleotides has been shown to have greatly
increased potency for silencing activity compared to an
unmodiﬁed construct with the same sequence (6). Since this
modiﬁed construct contained no RNA nucleotides, it was not
clear whether it was using a RISC-mediated siRNA method
of action.
In these preliminary studies, we demonstrate that OMe/
F-modiﬁed siRNA designed to hybridize to the gene Eg5
are 10-fold more potent than unmodiﬁed siRNA. We have
conﬁrmed that the modiﬁed siRNA activity is mediated by
the RISC. Ago2 leads to cleavage of the mRNA target at
the same position with both unmodiﬁed siRNA and OMe/
F-modiﬁed siRNA. Previously, it has been shown with
unmodiﬁed siRNAs that inactive siRNAs can compete with
active siRNAs, but the mechanism of this competitive
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the same manner, the OMe/F-modiﬁed siRNAs can compete
with unmodiﬁed siRNA for RISC-mediated cleavage of target
RNA. Thus, these fully modiﬁed siRNAs appear to utilize the
same mechanism as unmodiﬁed siRNAs and serve as a potent
tool to inhibit target genes in vitro.
MATERIALS AND METHODS
Cells and reagents
Tissue culture medium, trypsin and Lipofectamine2000 were
purchased from Invitrogen (Carlsbad, CA). HeLa, and U87-
MG cells were obtained from the American Type Tissue
Collection (Manassas, VA) and cultured in DMEM supple-
mented with 10% fetal calf serum, streptomycin (0.1 mg/
ml), and penicillin (100 U/ml). siRNA treatment was per-
formed using Opti-MEM (Invitrogen) containing 5 mg/ml
Lipofectamine2000 and the indicated amount of siRNA for
4ha t3 7  C, as described previously (14,15).
Preparation of synthetic siRNA
Synthetic unmodiﬁed siRNAs were purchased from
Dharmacon Research, Inc (Boulder, CO). Sequences of the
oligoribonucleotides and their respective modiﬁcations are
shown below. siRNA duplexes were formed according to
the manufacture’s instructions. In brief, 1.6 ml of a 250 mM
antisense stock was combined with 1.6 mlo fa2 5 0mM
sense stock, 4 mlo f5 · universal buffer (500 mM potassium
acetate, 150 mM HEPES–KOH, pH 7.4, 10 mM magnesium
acetate) and 12.8 ml of ultra-pure water followed by heating
at 90 C for 1 min. The reaction was then allowed to cool to
ambient temperature. The ﬁnal concentration of the duplex
was 20 mMi n1 · universal buffer (100 mM potassium acet-
ate, 30 mM HEPES–KOH, pH 7.4, 2 mM magnesium acet-
ate). The sequence of the PTEN siRNA (341401_341391)
is AAGTAAGGACCAGAGACAA (sense) and TTGTCTCT-
GGTCCTTACTT (antisense). The sequence of the Eg5
siRNA (371864_371854) is CAACAAGGATGAAGTCTAT
(sense) and ATAGACTTCATCCTTGTTG (antisense). The
alternating OMe/F-modiﬁed PTEN (359996_359995) and
Eg5 (372001_372002) siRNAs start with a 20-O-methylribose
followed by a 20-alpha-ﬂuoro-20-deoxyribose on the antisense
strands while the sense strands start with a 20-alpha-ﬂuoro-20-
deoxyribose followed by a 20-O-methylribose.
Cell-cycle analysis
Cells were grown on collagen coated 24-well plates and were
treated with the siRNAs (four replicates per group). Cells
were harvested 48 and 72 h after oligonucleotide treatment,
ﬁxed with 80% ethanol and stained with propidium iodide
(PI; Sigma, St Louis) containing RNAse cocktail, (Ambion,
Austin, TX). The PI-stained cells were analyzed on a
FACScan (BD Biosciences, San Jose). Cell-cycle proﬁle
was calculated with ModFit LT (Verity Softwear House,
Topsham, ME).
Taqman RT–PCR
Total RNA was harvested at 16–24 h post-transfection
using an RNeasy 3000 BioRobot (Qiagen, Valencia, CA).
Reduction of target mRNA expression was determined by
real time RT–PCR using an ABI Prism 7700 Sequence
Detector (Applied Biosystems, Foster City, CA). The
sequence for the human Eg5 primer/probe set used in the
RT–PCR reaction is GTGGTGAGATGCAGACCATTTAAT
for the forward primer, CTTTTCGTACAGGATCACATTC-
TACTATTG for the reverse primer and TGGCAGAGCG-
GAAAGCTAGCGC for the probe. The sequence for the
human PTEN primer/probe set is AATGGCTAAGTGAAG-
ATGACAAT for the forward primer, TGCACATATCA-
TTACACCAGTTCGT for the reverse primer andAGATGC-
CGTGTTTGATGGCTCCAGC for the probe.
Western blotting
siRNA treated cells were lysed in RIPA lysis buffer
containing 1% Triton X-100, 0.1% SDS, 0.25% Sodium
deoxycholate, 150 mM NaCl, Tris pH 7.5 and complete
protease inhibitor mix with EDTA (Roche, Indianapolis,
IN). Equal amounts of protein were resolved on a SDS–
PAGE gel and transferred to PVDF membranes. The mem-
branes were blocked for 1 h in PBS containing 0.1%
Tween-20 and 5% non-fat milk powder. Proteins were
detected using mouse anti-human Eg5 (BD Transduction
Laboratories). After incubation with peroxidase-coupled
secondary antibodies, blots were developed using ECL-plus
reagent (NEN) and exposed to X-ray ﬁlms (Kodak).
mRNA RISC cleavage assay
HeLa cells were seeded at an initial density of 1 000 000
cells/100 mm plate (Becton Dickinson, Franklin Lakes, NJ)
on the day prior to the initial transfection and incubated at
37 C, 5% CO2. Three 100 mm plates were used per siRNA
sample to be tested. Plasmid pE2-N_HA (expressing Ago2)
was delivered to cells (typically at 70–75% conﬂuency) by
using Effectene transfection reagent (Qiagen, Valencia, CA)
according to manufacture’s instructions and incubated for
2 4ha t3 7  C, 5% CO2. Synthetic siRNA (75 nM) was then
delivered to cells (typically at 80–85% conﬂuency) by
using Lipofectamine 2000 reagent (Invitrogen, Carlsbad,
CA) according to manufactures instructions. After 4 h at
37 C5 %C O 2, the media were aspirated from the cells and
replaced with DMEM containing 10% FBS and antibiotics
and returned to 37 C, 5% CO2 until cells were harvested
18 h later. Brieﬂy, cells were trypsinized, three 100 mm
plates per sample combined and cells pelleted by centrifuga-
tion. Cells were washed with 1 ml of cold PBS, and centri-
fuged at 1000 g. The cell pellet was resuspended in 500 ml
lysis buffer (150 mM NaCl, 0.5% NP-40, 2 mM MgCl2,
2m MC a C l 2, 20 mM Tris, pH 7.5) containing a Complete
Mini Protease Inhibitor Tablet (Roche, Indianapolis, IN)
and 1 mM DTT, then passed through a 1 cm
3 U-100 Insulin
Syringe (Becton Dickinson, Franklin Lakes, NJ) 10 times,
followed by a 10 min 10 000 g clearing spin. The supernatant
(450 ml) was transferred to a new tube containing 15 mlo f
immobilized HA.11 beads (Covance, Richmond, CA) and
535 ml lysis buffer. Beads were rotated end-over-end for
2 h, then washed 3· in wash buffer (500 mM NaCl, 2 mM
MgCl2, 2 mM CaCl2, 20 mM Tris, pH 7.5) followed by
one wash with cleavage buffer (100 mM KCl, 2 mM
MgCl2, 10 mM Tris, pH 7.5). Following the ﬁnal wash, the
4468 Nucleic Acids Research, 2006, Vol. 34, No. 16immunoprecipitated RISC complexes were incubated for 2 h
at 30 C in a heated mixer. Final reaction volume was 30 ml
containing 5 U/ml RNase, 1 mM ATP, 0.2 mM GTP, and
labeled target substrate in cleavage buffer. The reaction was
stopped by the addition of TRIZOL, followed by RNA
extraction according to the manufacture’s protocol and
PAGE analysis.
In vivo cleavage assay
1 · 10
6 HeLa cells were plated in a 100 mm dish. The follow-
ing day cells were transfected with 5 nM siRNA using 5 mg/
ml Lipofectamine 2000 (Invitrogen, Carlsbad, CA). 18 h later
total RNA was isolated with RNeasy spin columns (Qiagen,
Valencia, CA). One microgram of total RNA was ligated to
GeneRacer RNA oligo (Invitrogen, Carlsbad, CA). Omitting
CIP and TAP treatment restricts ligating GeneRacer oligo to
cleaved RNA. The ligated products were reverse transcribed
using Superscript III Reverse transcriptase (Invitrogen,
Carlsbad, CA) and a reverse Primer (50-CTGGATTTGAC-
GGCTCCTCTACTGTT-30 for PTEN and 50-TGAGTTCCT-
GTGAGAAGCCATCAG-30 for Eg5). A PCR step was
performed with a nested gene speciﬁc reverse primer (50-
CGGCTGAGGGAACTCAAAGTACATGA-30 for PTEN
and 50-TCAGCTCCTCCTCAACAGCACCAATT-30 for Eg5)
and a forward primer to the GeneRacer oligo. The resulting
PCR fragments were cloned into TOPO-TA cloning vector
(Invitrogen, Carlsbad, CA) and sequenced using T3 and T7
universal primers.
RESULTS
Activity of unmodified siRNA versus chemically
modified siRNA
Unmodiﬁed siRNA are unstable in vivo, and it is generally
agreed that chemical modiﬁcation or formulation will be
necessary to display potent systemic activity in vivo. For
this reason, we performed a structure-activity relationship
study to identify potent chemically-modiﬁed siRNA. We per-
formed a screen with 19mer siRNAs to ﬁnd chemistries that
are more nuclease resistant. Previously, we have shown that
PTEN siRNA, consisting entirely of alternating 20-O-methyl
and 20-ﬂuoro (OMe/F) nucleotides, display similar or
increased in vitro potency compared to unmodiﬁed siRNA
(Figure 1A), depending on the mRNA target site, increased
TM and enhanced plasma stability (6). The potencies of the
PTEN siRNA and OMe/F used throughout the studies are
shown in Figure 1A for both U87-MG human gliobloastoma
cells (left panel) and HeLa cells (right panel).
To investigate whether the incorporation of the OMe/F
modiﬁcation into other siRNA sequences will increase
potency against other molecular targets, we tested siRNAs
with alternating OMe and 20-ﬂuoro targeting the cell-cycle
regulating gene Eg5. Modiﬁed and unmodiﬁed siRNA
duplexes were transfected into U87-MG cells (Figure 1B,
left panel) and HeLa cells (Figure 1B, right panel) and
in vitro potency was determined by measuring mRNA reduc-
tion by quantitative RT–PCR. The potency of the OMe/F-
modiﬁed Eg5 siRNA compared to unmodiﬁed siRNA was
increased 40-fold in U87-MG and 7-fold in HeLa cells
(Figure 1B), respectively. Consistent with a decrease in Eg5
mRNA we also observed a dose-dependent decrease in Eg5
protein (Figure 1C).
Previously, we have demonstrated that inhibiting Eg5 with
an RNAse H antisense oligonucleotide (ASO) leads to a
G2/M-arrest, followed by an increase in apoptosis (16). We
also wanted to determine if inhibition of Eg5 with the modi-
ﬁed siRNA resulted in the same phenotype. Both the unmodi-
ﬁed siRNA and the OMe/F-modiﬁed siRNA led to an
increase in G2/M and an increase in subG1 cells (hypodiploid
cells) in U87-MG cells (Figure 2A) and HeLa cells
(Figure 2B). In agreement with the Eg5 mRNA data, the
OMe/F-modiﬁed siRNA was more potent and effective
compared to the unmodiﬁed siRNA in arresting cells in
G2/M and inducing apoptosis. The PTEN siRNAs did not
affect any of the cell cycle parameters.
Ago2 cleavage of mRNA with unmodified and
chemically modified siRNA
To investigate the mechanism by which the chemically modi-
ﬁed siRNA reduced Eg5 mRNA, we next utilized an Ago2
based in vitro RNA cleavage assay to conﬁrm that initial
cleavage of the targeted mRNA by the modiﬁed OMe/F
duplexes is a direct consequence of Ago2/RISC activity
(17–20). In brief, HeLa cells were ﬁrst transfected with a
vector expressing HA-tagged Ago2, and then 24 h later trans-
fected with the siRNAs. RISC complexes were allowed to
assemble endogenously for an additional 24 h, after which
cells were lysed and the HA-Ago2 RISC complexes were
immunoprecipitated with the anti-HA antibody. Following
isolation of the Ago2 complex, an RNA cleavage assay was
performed using a 40 nt
32P-50-labeled RNA substrate corres-
ponding to the region containing the target site for the trans-
fected siRNA. Both the unmodiﬁed and the OMe/F-modiﬁed
siRNA result in the same cleavage product, i.e. 10 nt from the
50 end of the antisense-strand (Figure 3A). To conﬁrm that the
siRNA leads to the same cleavage of endogenous mRNA
in cells, we also performed an in vivo cleavage assay. The
cleaved mRNA products for both Eg5 (Figure 3B) and
PTEN (Figure 3C) were cloned and sequenced. Both
the unmodiﬁed and the OMe/F-modiﬁed siRNA result in
the same cleavage product, i.e. 10 nt from the 50 end
of the guide-strand consistent with the in vitro results in
Figure 3A. Both PTEN and Eg5 OMe/F-modiﬁed siRNAs
led to cleavage at the same position as the unmodiﬁed
siRNA. These results demonstrate that the OMe/F-modiﬁed
siRNA complexes to Ago2 and cleaves targeted mRNA at
the same site as the unmodiﬁed siRNA.
F/OMe modified siRNAs compete with unmodified
siRNA
Previous work has suggested that RISC components may be
rate limiting to siRNA potency, as combining two siRNA res-
ults in loss of activity (13). To determine whether chemically
modiﬁed siRNA molecules can also compete with siRNA
loading into RISC, and whether this correlates with increased
potency, we tested PTEN and Eg5 siRNA for their ability to
compete with each other in U87-MG cells. Cotransfecting
either 10 or 50 nM unmodiﬁed PTEN siRNA shifted the
dose response curve of Eg5 siRNA by 10- or 100-fold,
Nucleic Acids Research, 2006, Vol. 34, No. 16 4469Figure 1. Target reduction with unmodified and OMe/F-modified siRNA. U87-MG and HeLa cells were transfected with increasing concentrations of PTEN (A)
and Eg5 (B) targeting siRNA (closed diamond, OMe/F; closed square, unmodified siRNA) and 24 h later PTEN and Eg5 mRNA expression was determined,
respectively. Data represent means ± SD of three replicates. (C) HeLa cells were transfected with increasing concentrations of Eg5 OMe/F and Eg5 protein
expression was measured 48 h later by western blotting. Lane 1 and 7: untreated control, lane 2–6 control OMe/F-treated (0.05, 0.2, 1, 10 and 50 nM), lane 8–12
Eg5 OMe/F-treated (0.05, 0.25, 1, 10 and 50 nM).
4470 Nucleic Acids Research, 2006, Vol. 34, No. 16Figure 2. Effect on inhibiting Eg5 expression on cell-cycle in U87-MG (A) and HeLa cells (B). Cells were transfected with increasing concentrations of Eg5
and PTEN targeting siRNA (closed diamond, Eg5 siRNA; closed square, Eg5 OMe/F; closed circle, PTEN siRNA; closed triangle, PTEN OMe/F), and 48 h later
cell-cycle profile was determined. Hypodiploidy represents cells with fragmented DNA as a measure of apoptosis while 4N represents mitotic cells or cells with
two nuclei.
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PTEN siRNA would compete with a constant concentration
(5 nM) of Eg5 siRNA. No effect was observed at concentra-
tions <5 nM. Concentrations >5 nM PTEN siRNA was
required to compete with 5 nM Eg5 siRNA (Figure 4B).
The PTEN siRNA with two dT-overhangs competes with
Eg5 siRNA comparable to the blunt end PTEN siRNA
(data not shown).
Next, we tested whether the OMe/F-modiﬁed siRNAs are
capable of competing with unmodiﬁed siRNA. Activity of
the unmodiﬁed Eg5 siRNA was inhibited to a similar degree
with OMe/F-modiﬁed PTEN siRNA (Figure 4C) as it was
with the unmodiﬁed PTEN siRNA in U87-MG cells
(Figure 4A). In HeLa cells, unmodiﬁed PTEN siRNA com-
peted with Eg5 siRNA (Figure 4D). Similarly, OMe/F-
modiﬁed PTEN siRNA competed with unmodiﬁed Eg5
siRNA (Figure 4E). However, higher concentrations were
required for competition than in U87-MG cells. To ensure
the competition seen is speciﬁc for siRNA, we next evaluated
the ability of a single stranded oligonucleotide that functions
through an RNase H mechanism of action to compete with
unmodiﬁed Eg5 siRNA. This compound had no effect on
Eg5 siRNA potency (Figure 5A). As with unmodiﬁed Eg5
siRNA the RNAse H antisense ASO was unable to compete
with the OMe/F-modiﬁed Eg5 siRNA using concentrations as
high as 200 nM. In the same experiment, PTEN mRNA
reduction with the PTEN ASO alone was the same as with
the combination of the OMe/F-modiﬁed Eg5 siRNA and
the PTEN ASO (data not shown).
Correlation between siRNA potency and competition
So far, we have tested if PTEN siRNA competes with Eg5
siRNA. We then evaluated whether the Eg5 unmodiﬁed
A
Figure 3. Modified siRNAs enter into the Ago2/RISC complex to mediate target RNA cleavage. (A)A5 0 end-labeled PTEN 40mer substrate was incubated
with immunopurified RISC complexes. Cleavage products were resolved on a 12% polyacrylamide–7 M urea gel. The 50 cleavage products are indicated by
arrows. Sequence identity was assigned according to the control digestions of the substrate by RNase T1 and OH hydrolysis. (B and C) In vivo cleavage of
Eg5 (B) and PTEN (C). GeneRacer clones obtained were cloned and sequenced to determine siRNA cleavage site. The cleavage relative to the siRNA is shown
above the gel.
4472 Nucleic Acids Research, 2006, Vol. 34, No. 16siRNA could compete with the unmodiﬁed PTEN
siRNA. The unmodiﬁed Eg5 siRNA failed to compete
with the unmodiﬁed PTEN siRNA (Figure 6A), while the
OMe/F-modiﬁed Eg5 siRNA at 10 and 50 nM competed,
resulting in a decrease in potency of the unmodiﬁed Eg5
siRNA (Figure 6B). The unmodiﬁed PTEN siRNA is about
ﬁve times more potent than the unmodiﬁed Eg5 siRNA
while the OMe/F-modiﬁed Eg5 siRNA is about four times
as potent as unmodiﬁed PTEN siRNA suggesting that there
is a correlation between potency and ability to compete.
In addition, we used four PTEN siRNAs with different poten-
cies to reduce PTEN mRNA (Figure 6C, upper panel). Three
of the PTEN siRNAs competed with the Eg5 siRNA,
while the PTEN siRNA with the lowest potency failed to
compete with the Eg5 siRNA (Figure 6C, lower panel).
This further indicates that very potent siRNAs also are
good competitors.
DISCUSSION
In order to develop siRNA with improved pharmacodynamic
and pharmacokinetic properties, we have synthesized a series
of siRNAs with alternating 20-O-methyl/20-ﬂuoro modiﬁca-
tions in both the sense and antisense strands. These modiﬁed
constructs have been shown to be more potent and more
Figure 4. PTEN siRNA competes with Eg5 siRNA. (A) U87-MG cells were transfected with increasing concentrations of Eg5 siRNA alone (closed diamond), or
in combination with 10 nM (closed square) or 50 nM (closed triangle) PTEN siRNA, respectively. (B) 5 nM of Eg5 siRNA was cotransfected with increasing
concentrations of PTEN siRNA (·). (C) Increasing concentrations of Eg5 siRNA was cotransfected with either 10 nM (closed square) or 50 nM (closed triangle)
PTEN OMe/F, respectively. (D and E) HeLa cells were transfected with increasing concentrations of Eg5 siRNA alone (closed diamond), or in combination with
50 nM (closed triangle) PTEN siRNA or 50 nM (closed triangle) PTEN OMe/F, respectively.
Nucleic Acids Research, 2006, Vol. 34, No. 16 4473nuclease resistant than chemically unmodiﬁed siRNA.
Recently, an OMe/F-modiﬁed siRNA was found to have
greatly increased potency compared to an unmodiﬁed
siRNA (6). Here we found that OMe/F-modiﬁcation of a
siRNA targeting Eg5 results in a more potent construct in
both U87-MG and HeLa cells. The higher potencies with
OMe/F siRNA correlated directly with increased biological
responses, including increasing 4N-DNA content and apop-
tosis. The same biologic effects have been observed when
Eg5 expression was inhibited with RNase H-mediated
ASOs (16) further demonstrating that the phenotype observed
is characteristic for reduced Eg5 expression levels and not a
reﬂection of unspeciﬁc toxicity. In addition, PTEN OMe/F-
modiﬁed constructs displayed no obvious toxicities.
We demonstrated that the chemically modiﬁed siRNAs
like unmodiﬁed siRNA result in cleavage of mRNA through
Ago2 (Figure 3A). To further support the hypothesis
that OMe/F-modiﬁed siRNA use the same mechanism as
unmodiﬁed siRNA, we conducted competition studies. We
found that both unmodiﬁed and OMe/F-modiﬁed PTEN
siRNA competed with unmodiﬁed Eg5 siRNA. These two
PTEN constructs were approximately equipotent at reducing
PTEN mRNA and were equally good competitors of Eg5
siRNA. In contrast, only the OMe/F-modiﬁed Eg5 construct
could effectively compete with the unmodiﬁed PTEN con-
struct. The unmodiﬁed Eg5 construct had little or no effect
on the ability of the PTEN siRNA to reduce PTEN mRNA.
The OMe/F modiﬁed Eg5 is much more potent than the
unmodiﬁed Eg5 construct which led us to believe that
the ability to compete may be correlated to the potency of
the constructs in reducing their targeted mRNA. To test
this, we used chemically-modiﬁed PTEN siRNA constructs
that had varying potencies for reducing PTEN mRNA. The
ability of these constructs to compete with an unmodiﬁed
Eg5 siRNA construct was correlated to their intrinsic poten-
cies. However, the correlation was not perfect, so there may
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4474 Nucleic Acids Research, 2006, Vol. 34, No. 16be other factors that also play a role in determining ability of
siRNAs to compete with each other.
There are also cell type differences in the competition of
siRNA constructs. In general, higher concentrations of com-
petitor siRNA were needed to see effects in HeLa cells com-
pared to U87-MG cells. This is demonstrated by the fact that
it required 50 nM PTEN siRNA to compete with Eg5 siRNA
in HeLa cells, but only 10 nM in U87-MG cells. Also, the low
potency unmodiﬁed Eg5 siRNA shows a limited ability to
compete with PTEN siRNA in U87-MG cells, but no com-
petition in HeLa cells. HeLa cells are probably the most fre-
quently used cell type in published siRNA studies. They seem
to have an excellent capacity for siRNA-mediated mRNA
cleavage relative to other cell lines. This may be due to
expression levels of proteins like Ago2, TRBP and PACT.
However, novel RISC components are still being discovered
and their roles in siRNA activity and cell type differences
remains to be elucidated (21).
The ability of siRNAs to compete is not limited to these
two targets as we also tested other siRNA constructs for
their ability to compete. We found siRNAs to genes other
than Eg5 and PTEN and also unspeciﬁc control siRNAs
were able to compete (data not shown). Despite the ability
of siRNAs to compete with each other, it is still possible to
inhibit more than one target simultaneously using appropriate
concentrations of siRNA. We have tested this with simultan-
eous treatment of PTEN and Eg5 siRNA and observed good
target reduction for both PTEN and Eg5 (data not shown).
However, the target reduction observed might be better
when cells are treated with one siRNA at a time. Simultan-
eous silencing of two genes has also been shown by others
(22). However, it is now clear that when attempting to silence
Figure 6. siRNA competition in U87-MG cells (A) Eg5 siRNA was unable to compete with PTEN siRNA in U87-MG cells. U87-MG cells were treated with
increasing concentrations of PTEN siRNA alone (closed diamond) or in combination with 10 nM (closed square) or 50 nM (closed triangle) Eg5 siRNA,
respectively. (B) Eg5 OMe/F competed with PTEN siRNA. U87-MG cells were treated with increasing concentration of PTEN siRNA alone (closed diamond) or
in combination with 10 nM (closed square) or 50 nM (closed triangle) Eg5 OMe/F, respectively. (C) Modified PTEN siRNAs with varying potencies to reduce
PTEN mRNA (top) show some ability to compete with an unmodified Eg5 siRNA (bottom). Bold characters are nucleotides with 20-O-methoxyethyl ribose-
modifications and underlined characters are nucleotides with OMe-modifications.
Nucleic Acids Research, 2006, Vol. 34, No. 16 4475two or more genes at once, one should be careful to use
appropriate siRNA concentrations to inhibit each target.
While we were writing this manuscript, Grimm et al. (23)
published the interesting ﬁnding that mice treated with high
doses of viral vectors carrying genes encoding shRNAs can
suffer from hepatotoxicity. This effect appeared to be caused
by the shRNAs competing with endogenous microRNAs for
mediated export from the nucleus. Exogenously added siR-
NAs were found to enter the nucleus and quickly get exported
by exportin-5 (24). Although in addition to exportin-5 there
might be other limiting factors contributing to saturation of
endogenous small RNA pathways. The exact implications
of this and our study for application of siRNA in drug discov-
ery efforts needs to be further evaluated. The wide spread in
vivo use of siRNA still awaits improvements in pharmacokin-
etic properties of siRNA constructs and additional work will
be needed to optimize efﬁcacy while taking care to prevent
interference with crucial endogenous siRNA/microRNA
pathways that might result in toxicity. Clearly more work is
needed to understand the molecular mechanism of how siR-
NAs can compete with each other and how exogenous
siRNA affects endogenous siRNA/microRNA pathways.
ACKNOWLEDGEMENTS
We thank Frank C. Bennett and Jon K. Bodnar for critical
reading of this manuscript. Funding to pay the Open Access
publication charges for this article was provided by Isis
Pharmaceuticals Inc.
Conflict of interest statement. None declared.
REFERENCES
1. Tomari,Y. and Zamore,P.D. (2005) Perspective: machines for RNAi.
Genes Dev., 19, 517–529.
2. Filipowicz,W. (2005) RNAi: the nuts and bolts of the RISC machine.
Cell, 122, 17–20.
3. Paddison,P.J., Cleary,M., Silva,J.M., Chang,K., Sheth,N.,
Sachidanandam,R. and Hannon,G.J. (2004) Cloning of short hairpin
RNAs for gene knockdown in mammalian cells. Nature Methods, 1,
163–167.
4. Manoharan,M. (2004) RNA interference and chemically modified
small interfering RNAs. Curr. Opin. Chem. Biol., 8, 570–579.
5. Manoharan,M. (2003) RNA interference and chemically modified
siRNAs. Nucleic Acids Res., 3, 115–116.
6. Allerson,C.R., Sioufi,N., Jarres,R., Prakash,T.P., Naik,N., Berdeja,A.,
Wanders,L., Griffey,R.H., Swayze,E.E. and Bhat,B. (2005) Fully
20-modified oligonucleotide duplexes with improved in vitro potency
and stability compared to unmodified small interfering RNA. J. Med.
Chem., 48, 901–904.
7. Prakash,T.P., Allerson,C.R., Dande,P., Vickers,T.A., Sioufi,N.,
Jarres,R., Baker,B.F., Swayze,E.E., Griffey,R.H. and Bhat,B. (2005)
Positional effect of chemical modifications on short interference RNA
activity in mammalian cells. J. Med. Chem., 48, 4247–4253.
8. Amarzguioui,M., Holen,T., Babaie,E. and Prydz,H. (2003) Tolerance
for mutations and chemical modifications in a siRNA. Nucleic Acids
Res., 31, 589–595.
9. Holen,T., Amarzguioui,M., Babaie,E. and Prydz,H. (2003) Similar
behaviour of single-strand and double-strand siRNAs suggests
they act through a common RNAi pathway. Nucleic Acids Res., 31,
2401–2407.
10. Czauderna,F., Fechtner,M., Dames,S., Aygun,H., Klippel,A.,
Pronk,G.J., Giese,K. and Kaufmann,J. (2003) Structural variations and
stabilising modifications of synthetic siRNAs in mammalian cells.
Nucleic Acids Res., 31, 2705–2716.
11. Kraynack,B.A. and Baker,B.F. (2006) Small interfering RNAs
containing full 20-O-methylribonucleotide-modified sense strands
display Argonaute2/eIF2C2-dependent activity. RNA,
12, 163–176.
12. Tuschl,T., Zamore,P.D., Lehmann,R., Bartel,D.P. and Sharp,P.A.
(1999) Targeted mRNA degradation by double-stranded RNA in vitro.
Genes Dev., 13, 3191–3197.
13. McManus,M.T., Haines,B.B., Dillon,C.P., Whitehurst,C.E., van
Parijs,L., Chen,J. and Sharp,P.A. (2002) Small interfering
RNA-mediated gene silencing in T lymphocytes. J. Immunol., 169,
5754–5760.
14. Dean,N.M., McKay,R., Condon,T.P. and Bennett,C.F. (1994)
Inhibition of protein kinase C-alpha expression in human A549 cells by
antisense oligonucleotides inhibits induction of intercellular adhesion
molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem., 269,
16416–16424.
15. Dean,N.M. and Griffey,R.H. (1997) Identification and characterization
of second-generation antisense oligonucleotides. Antisense Nucleic
Acid Drug Dev., 7, 229–233.
16. Koller,E., Propp,S., Zhang,H., Zhao,C., Xiao,X., Chang,M.,
Hirsch,S.A., Shepard,P.J., Koo,S., Murphy,C. et al. (2006) Use of a
chemically modified antisense oligonucleotide library to identify and
validate Eg5 (kinesin-like 1) as a target for antineoplastic drug
development. Cancer Res., 66, 2059–2066.
17. Martinez,J., Patkaniowska,A., Urlaub,H., Luhrmann,R. and Tuschl,T.
(2002) Single-stranded antisense siRNAs guide target RNA cleavage in
RNAi. Cell, 110, 563–574.
18. Liu,J., Carmell,M.A., Rivas,F.V., Marsden,C.G., Thomson,J.M.,
Song,J.J., Hammond,S.M., Joshua-Tor,L. and Hannon,G.J. (2004)
Argonaute2 is the catalytic engine of mammalian RNAi. Science, 305,
1437–1441.
19. Rivas,F.V., Tolia,N.H., Song,J.J., Aragon,J.P., Liu,J., Hannon,G.J. and
Joshua-Tor,L. (2005) Purified Argonaute2 and an siRNA form
recombinant human RISC. Nature Struct. Mol. Biol., 12, 340–349.
20. Song,J.J., Smith,S.K., Hannon,G.J. and Joshua-Tor,L. (2004) Crystal
structure of Argonaute and its implications for RISC slicer activity.
Science, 305, 1434–1437.
21. Lee,Y., Hur,I., Park,S.Y., Kim,Y.K., Suh,M.R. and Kim,V.N. (2006)
The role of PACT in the RNA silencing pathway. EMBO J., 25,
522–532.
22. Schuck,S., Manninen,A., Honsho,M., Fullekrug,J. and Simons,K.
(2004) Generation of single and double knockdowns in polarized
epithelial cells by retrovirus-mediated RNA interference. Proc. Natl
Acad. Sci. USA, 101, 4912–4917.
23. Grimm,D., Konrad,L., Streetz,C.L., Jopling,T.A., Storm,K.P.,
Davis,C.R., Marion,P., Salazar,F. and Kay,M.A. (2006) Fatality in
mice due to oversaturation of cellular microRNA/short hairpin RNA
pathways. Nature, 441, 537–541.
24. Ohrt,T., Merkle,D., Birkenfeld,K., Echeverri,C.J. and Schwille,P.
(2006) In situ fluorescence analysis demonstrates active siRNA
exclusion from the nucleus by Exportin 5. Nucleic Acids Res., 34,
1369–1380.
4476 Nucleic Acids Research, 2006, Vol. 34, No. 16